|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-07-1951.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Department of Medicine, VA Boston Healthcare
System; and the Department of Medicine, Brigham and
Women's Hospital and Harvard Medical School, Boston, MA.
Lactadherin, a glycoprotein of the milk-fat globule membrane,
contains tandem C domains with homology to discoidin-type lectins and
to membrane-binding domains of blood-clotting factors V and VIII. We
asked whether the structural homology confers the capacity to compete
for the membrane-binding sites of factor VIII and factor V and to
function as an anticoagulant. Our results indicate that lactadherin
competes efficiently with factor VIII and factor V for binding sites on
synthetic phosphatidylserine-containing membranes with
half-maximal displacement at lactadherin concentrations of 1 to 4 nM.
Binding competition correlated to functional inhibition of factor
VIIIa-factor IXa (factor Xase) enzyme complex. In contrast to annexin
V, lactadherin was an efficient inhibitor of the prothrombinase and the
factor Xase complexes regardless of the degree of membrane curvature
and the phosphatidylserine content. Lactadherin also inhibited the
factor VIIa-tissue factor complex efficiently whereas annexin V was
less effective. Because the inhibitory concentration of lactadherin was
proportional to the phospholipid concentration, and because lactadherin
was not an efficient inhibitor in the absence of phospholipid, the
major inhibitory effect of lactadherin relates to blocking phospholipid
sites rather than forming inhibitory protein-protein complexes.
Lactadherin was also an effective inhibitor of a modified whole blood
prothrombin time assay in which clotting was initiated by dilute tissue
factor; 60 nM lactadherin prolonged the prothrombin time 150% versus
20% for 60 nM annexin V. These results indicate that lactadherin can
function as a potent phospholipid-blocking anticoagulant.
(Blood. 2003;101:2628-2636) Lactadherin is a 47 000-Da molecular weight
(MW) glycoprotein of milk-fat globules. It has
also been known as PAS-6/7, indicating the 2 glycosylation
variants,1 bovine-associated mucoprotein, BA-46, P47, and
MFG-E8.2 Lactadherin has a domain structure of
EGF1-EGF2-C1-C2 in which EGF indicates epidermal growth factor homology domains, and the C domains share homology with the discoidin family, including the lipid-binding C domains of blood coagulation factor VIII and factor V.2 The second EGF domain displays
an Arg-Gly-Asp motif,3 which binds to the
In milk-fat globules, lactadherin lines the surface of the phospholipid
bilayer that surrounds the central triglyceride droplet, apparently
stabilizing the bilayer.7 Lactadherin decreases the
symptoms of rotavirus infection in infants, possibly by binding to
rotavirus particles via carbohydrate moieties.8 In tissue sections, lactadherin is found localized on the apical portion of
secretory epithelium in the breast.7 Abundant expression by breast carcinoma tissue makes lactadherin a potential target for
antigen-guided radiation therapy.9 Lactadherin is also found on the apical surface of epithelia in the biliary tree, the
pancreas, and sweat glands7 and is synthesized by aortic medial smooth muscle cells.10 Function in these tissues
remains unknown. Lactadherin has been identified as a zona
pellucida-binding protein on the acrosomal cap of sperm.11
Blood coagulation factor VIII and factor V bind to phospholipid
membranes via C domains that share homology with
lactadherin.12-14 Remarkable features of
membrane binding for these proteins include high affinity (dissociation
constant [Kd] of approximately 2 nM)15 and sufficient specificity so that no plasma
proteins compete for membrane-binding sites.16 Factor VIII
binds via stereoselective interaction with the
phospho-L-serine motif of phosphatidylserine (PS).17 Factor V also exhibits stereoselective interaction
with PS.18 Binding of factor VIII is enhanced by the
presence of phosphatidylethanolamine (PE) in the
membrane,19 by unsaturated phospholipid acyl
chains,20 and by membrane curvature.19 The crystal structures of the C2 domains of factors VIII and V suggest that
membrane binding is mediated by 2 pairs of hydrophobic residues displayed at the tips of Annexin V, like factor VIII and factor V, exhibits high-affinity,
PS-dependent membrane binding.26 However, the
quadruplicate membrane-binding motifs of annexin V are not homologous
with the discoidin-like domains of lactadherin, factor VIII, and factor V.27 Corresponding to the difference in structure, the
membrane-binding mechanism is different. Annexin V requires
Ca++ for membrane binding, and the binding is chiefly
hydrophilic.28 Annexin V does have the capacity to compete
for a fraction of the phospholipid-binding sites used by the factor
VIIIa-factor IXa enzyme complex and the factor Xa-factor Va enzyme
complex of the coagulation cascade so that it functions in vitro as a membrane-blocking anticoagulant.29 The well-defined
membrane-binding and anticoagulant properties of annexin V make studies
with annexin V suitable controls for studies with lactadherin.
The present study was undertaken to determine whether lactadherin could
function as an anticoagulant by competing with factor VIII for
membrane-binding sites. Our results indicate that lactadherin competes
efficiently for membrane-binding sites of factor VIII, inhibiting the
intrinsic pathway of coagulation. Lactadherin also inhibited the
prothrombinase complex and the factor VIIa-tissue factor complex,
implying that lactadherin competes for membrane-binding sites of other
coagulation proteins. Lactadherin also inhibited clotting of whole
blood, suggesting that lactadherin is also able to inhibit coagulation
reactions on cell membranes.
Materials
Evaluation and storage of proteins
Preparation of phospholipid vesicles Phospholipid vesicles were prepared by evaporating chloroform from the desired phospholipids (PS-PE-PC percentage ratio, 4:20:76 and 15:20:65), resuspending in methylene chloride, and re-evaporating twice under argon. Phospholipids were then suspended by gently swirling Tris (tris(hydroxymethyl)aminomethane)-buffered saline (50 mM Tris, 150 mM NaCl, pH 7.4) over the dried lipid suspension until all lipid was suspended. Vesicles prepared in this way were used as large multilamellar vesicles (LMVs).31 Some of the resuspended vesicles were then sonicated in a high-intensity bath sonicator (Laboratory Supplies, Hicksville, NY),32 and some were made by extruding these phospholipid suspensions 20 times through 2 stacked polycarbonate membranes (Millipore, Bedford, MA) in a High Pressure Extrusion Device (Sciema Technical Services, Vancouver, BC, Canada) under argon as described previously.33 Phospholipid concentration was determined by phosphorus assay.34 Vesicles were used fresh; or 1 mL aliquots were quick-frozen in liquid nitrogen, stored at 80°C, and thawed at
37°C. Storage at 4°C before incubation with microspheres or blood
clotting factors did not exceed 24 hours.
Relipidation of tissue factor Recombinant human tissue factor was relipidated into phospholipid vesicles of the indicated composition by means of the octyl- -D-glucopyranoside method.35 The nominal molar
ratio of tissue factor to phospholipid monomer was 1:7500.
Fluorescein-Glu-Gly-Arg chloromethyl ketone labeling of factor IXa Factor IXa was labeled with fluorescein-Glu-Gly-Arg chloromethyl ketone (Haematologic Technologies), essentially as described for the dansyl-Glu-Gly-Arg chloromethyl ketone.36 Free fluorescein-peptide was removed by ultrafiltration (Centricon 30) (Millipore). Labeling efficiency, as judged by the ratio of absorbance at 280 nm to absorbance at 490 nm, divided by extinction coefficients for factor IXa and fluorescein, was 0.2 fluorescein-peptide to 1 factor IXa.Flow cytometry binding assay Lipospheres were prepared as previously described.16 Glass microspheres of 1.6-µm nominal diameter (Duke Scientific, Palo Alto, CA) were cleaned, size-restricted, incubated with sonicated vesicles of the indicated composition, and washed 3 times in 0.15 M NaCl, 0.02 M Tris-HCl, 0.1% defatted bovine albumin, and 10 µM egg PC as sonicated vesicles. Lipospheres were stored at 4°C and used within 8 hours of synthesis. Recombinant human factor VIII and purified human factor V were labeled with fluorescein maleimide as described.37 Fluorescein-labeled factor VIII (4 nM) or fluorescein-labeled factor V (4 nM) was incubated with lactadherin or annexin V for 15 minutes at room temperature; the mixture was added to lipospheres for an additional 10 minutes; and membrane-bound factor VIII or factor V was measured by flow cytometry. This procedure was performed on 25-µL aliquots of 125-µL samples with an approximate liposphere concentration of 1 × 106/mL by means of a Becton Dickinson (San Jose, CA) FACSCalibur flow cytometer. Data acquisition was triggered by forward light scatter with all photomultipliers in the log mode. Noise was reduced during analysis by eliminating events with forward and side scatter values different from those characteristic of the lipospheres. Mean log fluorescence was converted to linear fluorescence for values depicted in the Figures. Only experiments in which the fluorescence histogram indicated a log-normal distribution, as judged by inspection, were analyzed quantitatively. Flow cytometry experiments were performed in 0.14 M NaCl, 0.02 M Tris-HCl, 1.5 or 5 mM CaCl2 as indicated in Figure legends, and 0.1% bovine albumin, pH 7.5.Mathematical model Competition of lactadherin for phospholipid-binding sites of factor VIII was compared with the following model, fVIIIB/fVIIIB(max) = [fVIII]/{[Kd × (1 + [lactadherin]/Ki)]+ [fVIII]}, where fVIIIB is membrane-bound factor VIII, fVIIIB(max) is maximum bound factor VIII when the concentration of factor VIII is saturating, Kd is the dissociation constant of factor VIII with phospholipid-binding sites, and Ki is the dissociation constant of lactadherin with the binding sites recognized by factor VIII. The model assumes that phospholipid-binding sites are limiting. For the curves depicted in Figures 1 through 3, all data were normalized to the calculated value of fVIIIB/fVIIIB(max) at the indicated concentrations of factor VIII without lactadherin. For factor Xase complex activity, fVIIIB/fVIIIB(max) was assumed to be proportional to residual activity. Curve fitting was by eye while Ki was varied, as the concentrations of factor VIII and lactadherin were known and the Kd value for factor VIII16 had been determined experimentally (Figure 1). The same model, substituting fV for fVIII, was used for comparison with competition binding experiments using factor V and with inhibition of the prothrombinase complex.
Factor Xase assay The activation of factor X by factor IXa in the presence of lactadherin or annexin V was measured with a 2-step amidolytic substrate assay30 with the following modifications. Factor IXa, 0.1 nM, was incubated with the specified concentrations of factor X and varied concentrations of lactadherin and annexin V in 150 mM NaCl, 50 mM Tris (pH 7.4), 1.5 mM CaCl2 (for 4% PS-sonicated vesicles), or 5 mM CaCl2 (for the other vesicles), 1 nM factor VIII, and 0.1 nM thrombin for 5 minutes at 25°C; final reaction volume was 40 µL. The reaction was then stopped by the addition of EDTA (ethylenediaminetetraacetic acid) to 7 mM final concentration. The amount of factor Xa generated was determined immediately with the use of the chromogenic substrate S-2765 (0.31 mg/mL) on a Molecular Devices (Sunnyvale, CA) enzyme-linked immunosorbent assay (ELISA) plate reader in kinetic mode. The results displayed in the Figures are the means of duplicates from a representative experiment. For studies without phospholipid, 40 nM factor IXa was mixed with 40 nM factor VIII and 250 nM factor X in the reaction buffer. The reaction was started by the addition of 2 nM thrombin and 1.5 mM Ca++. The reaction was allowed to proceed for 30 minutes prior to quenching with EDTA and reading, as above.Factor VIIa-tissue factor assay Relipidated tissue factor, at the indicated concentration, was mixed with 100 nM factor X, 0.1 nM factor VIIa, and varied concentrations of lactadherin or annexin V. The reaction was started by addition of 1.5 mM CaCl2 and allowed to proceed for 5 minutes at 25°C. The reaction was stopped with EDTA, and the quantity of factor Xa formed was determined as described above for the factor Xase assay.Prothrombinase assay Cleavage of prothrombin to thrombin was measured in a 2-step amidolytic substrate assay analogous to that for factor X activation as previously described.38 First, 1 nM factor Va, 6.2 pM factor Xa, and lactadherin or annexin V at specified concentrations were incubated for 5 minutes at 25°C in a solution containing 150 mM NaCl, 50 mM Tris, 1.5 mM (for 4% PS, sonicated vesicles) or 5 mM (for the other PS content and/or vesicle size) CaCl2, and 0.05% wt/vol ovalbumin, pH 7.8, prior to the addition of 1 µM prothrombin. After 5 minutes at 25°C, the reaction was stopped by the addition of EDTA to a final concentration of 7 mM. Thrombin formation was assessed in a kinetic microplate reader immediately after addition of 0.1 mM chromogenic substrate S-2238. The results displayed in the Figures are the means of triplicates from a representative experiment.Activated partial thromboplastin time and prothrombin time assays Pooled normal plasma, anticoagulated with 1:9 dilution of 3.8% citrate, was stored at80°C until use. All reagents were prewarmed to 37°C, and assays were performed in triplicate. For the activated partial thromboplastin time (aPTT) assay, 76 µL plasma was mixed with
76 µL aPTT reagent (aPTT-SA) (Helena Laboratories, Beaumont TX) and
76 µL lactadherin diluted into Tris-buffered saline. After 10 minutes, 76 µL 25 mM Ca++ was added to start the clotting
reaction. Time to fibrin-strand formation was measured with a
fibrometer. The aPTT reagent was either used at full strength or
diluted 1:16 in 100 µM ellagic acid, as indicated (to maintain a
constant ellagic acid concentration as the phospholipid was diluted).
For the prothrombin time (PT) assay, 100 µL plasma was mixed with 100 µL lactadherin in Tris-buffered saline and 100 µL PT reagent (Thromboplastin-C Plus) (Baxter, Miami, FL). Because package instructions call for use of the PT reagent at a 2:1 ratio with plasma, the PT reagent was supplemented with 16 mM Ca++ to achieve the manufacturer's intended final Ca++ concentration. The PT reagent was also diluted 1:24 in 16 mM Ca++, then used in the same manner as full-strength PT reagent. Whole-blood prothrombin time assay Blood was drawn from healthy, nonsmoking, non-aspirin-using volunteers by means of 19-gauge butterfly needles. The first 3 mL blood was discarded. Subsequently, 20 mL blood was gently drawn. The blood was rapidly discharged into a polypropylene tube containing sodium citrate, final concentration 10 mM. To suppress contact activation, corn trypsin inhibitor was added to the tube (final concentration, 25 µg/mL). The blood was kept at room temperature, gently mixed by inversion approximately every 10 minutes, and used within 3 hours of collection. For the clotting reaction, 150-µL aliquots of blood were prewarmed to 37°C for 10 minutes, then diluted 1:1 with 10 mM CaCl2, the indicated concentration of lactadherin or annexin V, and 50 pM relipidated tissue factor (0.38 µM phospholipid). The time to fibrin-strand formation was monitored with a fibrometer. Experiments were performed in triplicate.
We hypothesized that the tandem C domains of lactadherin confer phospholipid-binding properties that enable it to compete with factor VIII and/or factor V for membrane-binding sites and function as an anticoagulant. To test this hypothesis, we performed a competition membrane-binding experiment in which lactadherin competed with fluorescein-labeled factor VIII for membrane binding sites (Figure 1A). The membranes had a composition of 4% PS, 20% PE, and the balance as PC. Bilayers were supported on 2-µm-diameter glass microspheres (lipospheres), and binding of factor VIII was evaluated by flow cytometry.16 Lactadherin effectively competed for all factor VIII-binding sites, with half-maximal displacement occurring at approximately 1.5 nM lactadherin. The competition predicted by a mathematical model approximated the data when lactadherin was assigned a Ki of 0.5 nM. For comparison with lactadherin, we asked if annexin V would compete for factor VIII-binding sites in the same assay (Figure 1A). Annexin V competed for approximately 20% of factor VIII-binding sites at a concentration of 32 nM. These results indicate that lactadherin is a more potent competitor for the phospholipid-binding sites of factor VIII on membranes with 4% PS. To determine whether lactadherin is also able to recognize the phospholipid-binding sites of factor V, we performed similar competition experiments with fluorescein-labeled factor V (Figure 1B). Lactadherin competed efficiently for the binding sites recognized by factor V with half-maximal inhibition at an approximately 2-fold higher concentration. Annexin V competed for only 20% of the factor V-binding sites at concentrations up to 32 nM. The corresponding Ki for a curve approximating the data was 1.0 nM. We performed factor Xase assays in the presence of increasing concentrations of lactadherin to determine whether the competition for factor VIII-binding sites would translate into inhibition of the factor Xase complex (Figure 1C). The phospholipid composition of the sonicated vesicles used was the same as for the binding experiments depicted in Figure 1A. Lactadherin was a potent inhibitor of the factor Xase complex, with half-maximal inhibition at approximately 6 nM and greater than 98% inhibition at 32 nM. Annexin V was an ineffective inhibitor of the factor Xase complex with lower than 10% inhibition at 64 nM annexin V. These results confirm that lactadherin is able to inhibit the factor Xase complex, probably by competing with factor VIIIa and/or factor IXa and factor X for phospholipid-binding sites. They do not explain why annexin V, which also binds to phospholipid membranes with high affinity, is an ineffective inhibitor under these conditions. We asked whether lactadherin is capable of inhibiting the
prothrombinase complex in a manner similar to the factor Xase complex (Figure 2). Prior reports indicate that
membrane binding and anticoagulant efficacy of annexin V is related to
the PS content of membranes and inversely related to the curvature of
phospholipid membranes.39 Thus, we evaluated vesicles with
maximal curvature (sonicated, nominal diameter of 20 nm),40 intermediate curvature (extruded, nominal diameter
73 ± 25 nm),33 and minimal curvature (large multilamellar vesicles, diameters greater than 400 nm),31
with both low PS content (4% PS, Figure 2A-C) and high PS content
(15% PS, Figure 2D-F). The effectiveness of the vesicles for
supporting prothrombinase complex decreased as the curvature decreased,
with sonicated vesicles of 4% PS producing 90% of the maximum
thrombin production at a concentration of 0.1 µM phospholipid and
much higher concentrations required for extruded vesicles and large multilamellar vesicles (LMVs) (Figure 2A). We compared the
effects of lactadherin and annexin V on thrombin formation using the
phospholipid concentrations indicated by open symbols in Figure 2A. We
maintained the Ca++ concentration at 1.5 mM, equivalent to
plasma, for sonicated vesicles with 4% PS to test the reproducibility
of the results in Figure 1. However, we increased the Ca++
concentration to 5 mM for all other vesicles in order to optimize binding conditions for annexin V. Results showed that greater than 90%
inhibition of thrombin production was effected by lactadherin in
sonicated vesicles, extruded vesicles, and LMVs. Our results confirmed that sonicated vesicles provide a substantially more potent
surface for the prothrombinase complex than vesicles of larger
diameter, particularly when the PS content is 4%. In contrast, annexin
V was ineffective for sonicated vesicles and reached only 25% to 40%
inhibition on extruded vesicles and LMVs at 64 nM.
Lactadherin was an efficient inhibitor of the prothrombinase complex on all vesicles containing 15% PS (Figure 2E). The half-maximal inhibitory concentrations of lactadherin varied with vesicle type. The limiting concentrations of phospholipids for experiments in Figure 2B facilitated comparison of actual inhibition with that predicted by a Ki of 1.0 nM, as depicted in Figure 1B. (The term Ki is used to indicate only competition of lactadherin for binding sites of factor V(a) or factor VIII(a) when phospholipid-binding sites are limiting.) The inhibition curve approximates the data obtained with sonicated vesicles. The variation in the concentration of lactadherin required for different vesicle types (Figure 2B,E) could be rationalized by assuming that lactadherin binds well to all types of phospholipid vesicles and that the higher phospholipid concentrations of extruded vesicles and LMVs required more lactadherin to saturate the surface. In contrast to lactadherin, annexin V was an effective inhibitor on LMVs only when the PS content was 15% (Figure 2C,F). Under these conditions, annexin V inhibited approximately 90% of prothrombinase activity at 128 nM concentration, similar to results in a prior report.39,41 Annexin V was not as effective as lactadherin under any conditions evaluated. These results indicate that lactadherin efficiently inhibits the prothrombinase complex and that, in contrast to annexin V, inhibition is not closely tied to PS content or to vesicle curvature. We asked whether inhibition of the factor Xase complex by annexin V and
lactadherin may also be related to PS content of membranes and membrane
curvature (Figure 3). Our results
indicate that, like the prothrombinase complex, the factor Xase complex
is supported at lower concentrations of sonicated vesicles than
extruded vesicles or LMVs (Figure 3A,D). Also, the inhibition of the
Xase activity on sonicated vesicles was approximated by a model in
which lactadherin is assigned a Ki of 0.5 nM
(Figure 3B), similar to the value correlating to direct competition for
factor VIII-binding sites (Figure 1A). Lactadherin inhibited factor
Xase complex more than 95% on all vesicle types, similar to inhibition
of the prothrombinase complex (Figure 3B,E). However, the difference
between the lactadherin concentrations required for inhibition of the
factor Xase complex on sonicated versus extruded vesicles and LMVs was
not as large as for the prothrombinase complex (Figure 2B,E). Annexin V
was a more effective inhibitor of the factor Xase complex than the prothrombinase complex, with inhibition reaching 80% for LMVs of 4%
PS (Figure 3C) and 95% for LMVs of 15% PS (Figure 3F). However, annexin V remained a poor inhibitor of the factor Xase complex on
sonicated vesicles, with lower than 20% inhibition for 4% PS and
lower than 50% for 15% PS. Together, these results indicate that
lactadherin is a potent, near-complete inhibitor of the prothrombinase and factor Xase complexes on synthetic membranes regardless of membrane
curvature and over a wide range of PS content.
We asked whether lactadherin might also have the capacity to inhibit
the factor VIIa-tissue factor complex (Figure
4A). Recombinant tissue factor was
reconstituted into vesicles containing 4% PS and 20% PE by dialyzing
octylthioglucoside away from the tissue factor-phospholipid mixture.
Vesicles prepared in this way have curvature comparable to extruded
vesicles.42 Lactadherin inhibited the factor VIIa-tissue
factor complex more than 90%. The quantity of lactadherin required for
50% inhibition varied with the tissue factor concentration and
corresponding phospholipid concentration. Annexin V was a weaker
inhibitor of the factor VIIa-tissue factor complex (Figure 4B), with
lower than 50% inhibition at an annexin V concentration of 64 nM.
These results suggest that lactadherin has the capacity to compete for
membrane-binding sites of blood coagulation proteins other than factor
V and factor VIII.
To directly probe the possibility that lactadherin can compete with
vitamin K-dependent blood coagulation proteins for membrane binding,
we asked whether lactadherin is able to compete with fluorescein-labeled factor IXa (Figure
5). Fluorescein-labeled factor IXa bound
to lipospheres with a dissociation constant of approximately 0.5 µM
(data not shown), consistent with prior reports of the membrane-binding
affinity of factor IX/factor IXa. Unlabeled factor IXa competed with
fluorescein-labeled factor IXa, indicating that membrane binding was
not enhanced by derivatization by fluorescein-Glu-Gly-Arg chloromethyl
ketone at the active site. Lactadherin competed with fluorescein-labeled factor IXa for membrane-binding sites to the same
extent as unlabeled factor IXa. However, half-maximal inhibition occurred at approximately 4 nM lactadherin versus 300 nM factor IXa.
To confirm that the mechanism through which lactadherin inhibits
membrane-bound blood coagulation complexes is via competition for
membrane-binding sites, we performed experiments with varying phospholipid concentrations (Figure 6).
When the phospholipid vesicle concentration was limiting, lactadherin
inhibited 50% activity of the factor Xase complex (Figure 6A) and the
prothrombinase complex (Figure 6B) at a concentration of approximately
2 nM. The concentration required increased for each increment in the phospholipid concentration, indicating that the required lactadherin is
related to the phospholipid concentration rather than the
concentrations of blood coagulation proteins. Furthermore, when the
phospholipid concentration was 2.5 µM, the factor Xase complex and
prothrombinase complex maintained more than 90% activity at 8 nM
lactadherin, a concentration that inhibits activity more than 90% when
the phospholipid concentration is limiting. We also evaluated the effect of lactadherin on the factor VIIIa-factor IXa complex in the
absence of phospholipid (Figure 6C). The concentrations of factor
VIIIa, factor IXa, and factor X were chosen to be at or below their
apparent Kd's or KM's
(Michaelis constants), respectively, thus optimizing the
sensitivity of the reaction to inhibitory action of lactadherin.
Lactadherin caused lower than 50% inhibition at concentrations up to
512 nM. Thus, lactadherin is at least a 1000 times better inhibitor in
the presence of phospholipid membranes. These results suggest that the
only mechanism through which lactadherin inhibits the factor Xase and
prothrombinase complexes at the concentrations employed is by
competitive occupation of phospholipid-binding sites and that
protein-protein complexes between lactadherin and factor VIIIa, factor
Va, factor IXa, or factor X do not occur or do not significantly
inhibit function of these enzyme complexes.
To further investigate the dependence of lactadherin's inhibitory properties on phospholipid concentration, we evaluated inhibition of plasma clotting in aPTT and PT assays. Commercial aPTT and PT reagents contain high concentrations of phospholipids of unknown or unspecified composition. Lactadherin inhibited the aPTT assay by approximately 10% at a concentration of 1000 nM and had no effect at concentrations of 100 nM or lower. However, when the aPTT reagent was diluted to 6% of the original concentration, the aPTT was prolonged 5%, 20%, and 1000% at concentrations of 10, 100, and 1000 nM, respectively. Similarly, 1000 nM lactadherin inhibited the prothrombin time by less than 20% when the PT reagent was present at 50% of manufacturer's suggested usage. However, when the PT reagent was diluted to 2% of the stock concentration, the PT was prolonged 5%, 30%, and 500% by lactadherin concentrations of 10, 100, and 1000 nM, respectively. These results are consistent with the model in which the major mechanism through which lactadherin inhibits blood coagulation enzyme complexes is through competition for phospholipid-binding sites. Further studies, with defined phospholipid membranes, will be required to determine whether the apparent Ki's for inhibition of the isolated prothrombinase and Xase complexes correlate with inhibitory concentrations for plasma. These results, showing inhibition of the factor Xase, the
prothrombinase, and the factor VIIa-tissue factor complexes, support the hypothesis that lactadherin would inhibit the rate at which whole
blood clots. To test this prediction, we used a modified whole blood
prothrombin time (Figure 7). In this
assay, fresh blood was anticoagulated with citrate and corn trypsin
inhibitor (to minimize activation of the intrinsic pathway prior to the prothrombin time assay) in a polypropylene tube. Blood coagulation was
initiated by simultaneous addition of calcium and 50 pM tissue factor
prepared as in Figure 4. In the absence of lactadherin or annexin V,
the time to clotting varied between 1200 and 2000 seconds for
different donors. Lactadherin and annexin V led to prolongation of the
clotting time, and the prolongation was similar over a concentration
range of 0 to 20 nM. However, at concentrations of 40 nM and higher,
lactadherin led to progressively longer inhibition of blood clotting.
The clotting time was prolonged approximately 3-fold at 100 nM
lactadherin, but only about 1.5-fold by annexin V. These results
suggest that lactadherin is able to compete for binding sites on cell
membranes to inhibit blood coagulation in a manner similar to
inhibition of isolated blood coagulation complexes on phospholipid
vesicles.
Our results indicate that lactadherin binds to PS-containing membranes with sufficient affinity to compete with blood coagulation proteins. The phospholipid-binding competition makes lactadherin a potent inhibitor of the prothrombinase, the factor Xase, and the factor VIIa-tissue factor complexes of blood coagulation. Because the quantity of lactadherin necessary to inhibit these enzyme complexes is proportional to the phospholipid concentration used, and because lactadherin does not efficiently inhibit the phospholipid-free factor VIIIa-factor IXa complex, the major mechanism of inhibition involves blocking of the phospholipid surface rather than formation of inhibitory protein-protein complexes. Inhibition of whole blood prothrombin time suggests that lactadherin is able to bind to platelet membranes to inhibit blood coagulation by a mechanism similar to inhibition of reconstituted enzyme complexes on phospholipid vesicles. The enzyme complexes of blood coagulation assemble and function efficiently only on a membrane surface. PS-containing membranes serve to increase the apparent affinity of the cofactors factor VIIIa and factor Va for the enzymes factor IXa and factor X, respectively, and of the cofactor-enzyme complexes for the substrates factors X and prothrombin.43 The membranes also serve as allosteric activators of the enzyme-cofactor complex.30 PS-containing membranes also support anticoagulant activity that modulates the procoagulant activity. For example, protein C is activated by the thrombin-thrombomodulin complex on PS-containing membranes,44 and activated protein C inactivates factor Va and factor VIIIa on PS-containing membranes.45 The membranes of quiescent blood cells do not display the PS necessary to enable assembly and function of the procoagulant enzyme complexes.46,47 Rather, PS is exposed only after cells are stimulated or undergo apoptosis.48 In the setting of a tissue injury, the procoagulant membranes are probably on the surface of platelets that have adhered to the damaged tissues.49 The absence of a PS-containing phospholipid membrane effectively prevents function of the complexes. Thus, blocking the PS-containing phospholipid-binding sites on platelets appears to be a potential mechanism for preventing blood coagulation or altering the procoagulant/anticoagulant balance. Additional investigation will be necessary to determine whether lactadherin has this physiologic function. Several proteins have been identified that can influence blood
coagulation via interaction with phospholipid membranes. The hypothesis
that lactadherin might function in this manner was based on the
homology between the discoidin-type domains of lactadherin and those of
factors VIII and V, together with the previously defined
membrane-binding properties of lactadherin.6 Annexin V,
the most thoroughly studied of these proteins, binds to PS-containing membranes with high affinity.26 However, annexin V binds
poorly to curved membranes,41 requires supraphysiologic
Ca++ concentrations for optimal binding, and inhibits less
than 80% of procoagulant function on endothelial cell membranes unless the concentration exceeds 200 nM.50 Likewise, annexin V is
an incomplete inhibitor of the factor Xase complex on platelet
membranes.51 Our results, indicating that inhibition of
the prothrombinase complex exceeds 80% at 60 nM annexin V only when
the curvature of the membrane is minimal and the PS content is 15%,
are in agreement with these prior studies. The
Factor VIII binds to sites on phospholipid membranes with remarkable specificity. The specificity is best illustrated by the failure of other lipid-binding proteins to compete with factor VIII for these sites.16 Even factor V, with structural homology and equivalent affinity for phospholipid membranes, competes for only a fraction of the sites recognized by factor VIII. The capacity of lactadherin to compete for membrane-binding sites of factor VIII, as well as to inhibit both the factor Xase complex and the prothrombinase complex, implies that lactadherin is more promiscuous than factor VIII with regard to phospholipid-binding sites.16 Inhibition of the factor VIIa-tissue factor complex indicates that lactadherin has the capacity to compete for the vitamin K-dependent proteins, factor VIIa, and/or factor X. The contrast between lactadherin and annexin V with regard to competing for membrane sites of both high- and low-PS content and varying membrane curvature indicate that lactadherin is also more promiscuous in its membrane requirements than annexin V. To facilitate understanding of these properties, we have initiated studies to characterize the membrane-binding properties of lactadherin versus those of factor VIII and factor V. The results indicate that lactadherin resembles factor VIII and factor V in specific binding to PS and curvature-dependent membrane binding. However, lactadherin differs in having a lower PS requirement and no apparent requirement for PE on membranes with low PS content (J.S., E.W. Heegaard, J.T. Rasmussen, and G.E.G., manuscript in preparation). Comparing the displacement of factor VIII and factor V by lactadherin with the competition predicted from the simplest mathematical model (Figures 1-3) supports 2 conclusions. First, lactadherin is a better competitor for factor VIII-binding sites than for factor V-binding sites, with a Ki that is 2-fold lower. More potent competition for factor VIII-binding sites correlated with a 2-fold lower Ki for the factor Xase complex versus the prothrombinase complex, not only under conditions in which phospholipid was limiting but also when phospholipid was not limiting (Figure 6). The lower Ki implies that lactadherin binds with higher affinity to phospholipid-binding sites of factor VIII versus those of factor V. The second conclusion is that the experimental data did not precisely conform to the curves predicted by the mathematical model. The assumption of the model was that lactadherin competed for a single class of phospholipid-binding sites with factor VIII or factor V. In separate studies, we have further characterized the interaction of lactadherin with phospholipid-binding sites. Our results indicate that lactadherin recognizes at least 2 classes of phospholipid-binding sites, so both association and dissociation are kinetically complex events (J.S., E.W. Heegaard, J.T. Rasmussen, and G.E.G., manuscript in preparation). The ability to interact with multiple classes of phospholipid-binding sites probably explains part of the variation from the simple model as well as the mechanism underlying the capacity to compete with factor VIII and factor V with different apparent Ki's. The concentrations of lactadherin required to inhibit the whole blood prothrombin time were somewhat higher than the concentrations necessary to inhibit isolated enzyme complexes (compare Figures 2-4 versus Figure 6). Our data do not indicate whether these apparent discrepancies in concentration reflect lactadherin binding to a plasma protein that partially competes with binding sites on the membranes of platelets or other cells or whether lactadherin may have a lower affinity for cell membranes versus phospholipid vesicles. The results in this report suggest that lactadherin could serve as a physiologic or pharmacologic anticoagulant. In newborn calves, the plasma concentration rises from 0.07 µg/mL before feeding to 1.2 µg/mL after feeding, suggesting that intact lactadherin is absorbed across the gastrointestinal tract and that sufficient lactadherin circulates in the blood under these conditions to have a measurable in vitro anticoagulant effect.7 Lower concentrations of lactadherin have been measured in the serum of women with metastatic breast carcinoma, but not in the serum of healthy controls.57 The plasma levels in pregnant or lactating mammals have not been reported. However, it is plausible that sufficient lactadherin may be secreted into the blood or may "leak" from mammary glands to provide an anticoagulant effect during pregnancy or lactation. The relatively small size of lactadherin suggests that it freely traverses the placental barrier and could affect the procoagulant/anticoagulant balance of a developing fetus. The presence of lactadherin on the apical surfaces of secretory epithelia other than breast tissue suggests that lactadherin may circulate in blood even during the nonpregnant state. Thus, it is plausible that lactadherin could provide a physiologic anticoagulant function under a variety of circumstances. Our data suggest that lactadherin may be a candidate for development as a pharmacologic anticoagulant. Lactadherin functions at steps that are early in the coagulation pathway and is apparently more potent than annexin V, the only other tested agent that functions by a similar mechanism.
We are grateful to Drs C. W. Heegaard and J. T. Rasmussen for the generous gift of purified bovine lactadherin and for helpful suggestions on the manuscript.
Supported by grant R01 HL57867 from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health.
Submitted July 1, 2002; accepted November 6, 2002. Prepublished online as Blood First Edition Paper, November 27, 2002; DOI 10.1182/blood-2002-07-1951.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Gary E. Gilbert, VA Boston Healthcare System, 1400 VFW Pkwy, West Roxbury, MA 02132; e-mail: ggilbert{at}rics.bwh.harvard.edu.
1. Hvarregaard J, Andersen MH, Berglund L, Rasmussen JT, Petersen TE. Characterization of glycoprotein PAS-6/7 from membranes of bovine milk fat globules. Eur J Biochem. 1996;240:628-636[Medline] [Order article via Infotrieve].
2.
Stubbs J, Lekutis C, Singer K, et al.
cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidemal growth factor-like domains linked to factor VIII-like sequences.
Proc Natl Acad Sci U S A.
1990;87:8417-8421 3. Couto JR, Taylor MR, Godwin SG, Ceriani RL, Peterson JA. Cloning and sequence analysis of human breast epithelial antigen BA46 reveals an RGD cell adhesion sequence presented on an epidermal growth factor-like domain. DNA Cell Biol. 1996;15:281-286[Medline] [Order article via Infotrieve].
4.
Andersen MH, Berglund L, Rasmussen JT, Petersen TE.
Bovine PAS-6/7 binds 5. Taylor MR, Couto JR, Scallan CD, Ceriani RL, Peterson JA. Lactadherin (formerly BA46), a membrane-associated glycoprotein expressed in human milk and breast carcinomas, promotes Arg-Gly-Asp (RGD)-dependent cell adhesion. DNA Cell Biol. 1997;16:861-869[Medline] [Order article via Infotrieve]. 6. Andersen MH, Graversen H, Fedosov SN, Petersen TE, Rasmussen JT. Functional analyses of two cellular binding domains of bovine lactadherin. Biochemistry. 2000;39:6200-6206[CrossRef][Medline] [Order article via Infotrieve]. 7. Butler JE, Pringnitz DJ, Martens CL, Crouch N. Bovine-associated mucoprotein, I: distribution among adult and fetal bovine tissues and body fluids. Differentiation. 1980;17:31-40[CrossRef][Medline] [Order article via Infotrieve]. 8. Newburg DS, Peterson JA, Ruiz-Palacios GM, et al. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. Lancet. 1998;351:1160-1164[CrossRef][Medline] [Order article via Infotrieve].
9.
Peterson JA, Couto JR, Taylor MR, Ceriani RL.
Selection of tumor-specific epitopes on target antigens for radioimmunotherapy of breast cancer.
Cancer Res.
1995;55(suppl):5847s-5851s
10.
Haggqvist B, Naslund J, Sletten K, et al.
Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid.
Proc Natl Acad Sci U S A.
1999;96:8669-8674 11. Ensslin M, Calvete JJ, Thole HH, et al. Identification by affinity chromatography of boar sperm membrane-associated proteins bound to immobilized porcine zona pellucida: mapping of the phosphorylethanolamine-binding region of spermadhesin AWN. Biol Chem Hoppe Seyler. 1995;376:733-738[Medline] [Order article via Infotrieve]. 12. Arai M, Scandella D, Hoyer L. Molecular basis of factor VIII inhibition by human antibodies: antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest. 1989;83:1978-1984[Medline] [Order article via Infotrieve].
13.
Foster PA, Fulcher CA, Houghten RA, Zimmerman TS.
Synthetic factor VIII peptides with amino acid sequences contained within the C2 domain of factor VIII inhibit factor VIII binding to phosphatidylserine.
Blood.
1990;75:1999-2004
14.
Ortel T, Devore-Carter D, Quinn-Allen M, Kane W.
Deletion analysis of recombinant human factor V: evidence for a phosphatidylserine binding site in the second C-type domain.
J Biol Chem.
1992;267:4189-4198
15.
Gilbert GE, Furie BC, Furie B.
Binding of human factor VIII to phospholipid vesicles.
J Biol Chem.
1990;265:815-822
16.
Gilbert GE, Drinkwater D, Barter S, Clouse SB.
Specificity of phosphatidylserine-containing membrane binding sites for factor VIII: studies with model membranes supported by glass microspheres (lipospheres).
J Biol Chem.
1992;267:15861-15868 17. Gilbert GE, Drinkwater D. Specific membrane binding of factor VIII is mediated by O-phospho-L-serine, a moiety of phosphatidylserine. Biochemistry. 1993;32:9577-9585[CrossRef][Medline] [Order article via Infotrieve]. 18. Comfurius P, Smeets EF, Willems GM, Bevers EM, Zwaal RFA. Assembly of the prothrombinase complex on lipid vesicles depends on the stereochemical configuration of the polar headgroup of phosphatidylserine. Biochemistry. 1994;33:10319-10324[CrossRef][Medline] [Order article via Infotrieve].
19.
Gilbert GE, Arena AA.
Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine.
J Biol Chem.
1995;270:18500-18505 20. Gilbert GE, Arena AA. Unsaturated phospholipid acyl chains are required to constitute membrane binding sites for factor VIII. Biochemistry. 1998;37:13526-13535[CrossRef][Medline] [Order article via Infotrieve]. 21. Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 angstrom resolution. Nature. 1999;402:439-442[CrossRef][Medline] [Order article via Infotrieve]. 22. Macedo-Ribeiro S, Bode W, Huber R, et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature. 1999;402:434-439[CrossRef][Medline] [Order article via Infotrieve]. 23. Kim SW, Quinn-Allen MA, Camp JT, et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry. 2000;39:1951-1958[CrossRef][Medline] [Order article via Infotrieve].
24.
Gilbert GE, Kaufman RJ, Arena AA, Miao H, Pipe SW.
Four hydrophobic amino acids in the factor VIII C2 domain are constituents of the membrane-binding and von Willebrand factor-binding motif.
J Biol Chem.
2002;277:6374-6381 25. Peterson JA, Patton S, Hamosh M. Glycoproteins of the human milk fat globule in the protection of the breast-fed infant against infections. Biol Neonate. 1998;74:143-162[CrossRef][Medline] [Order article via Infotrieve].
26.
Tait JF, Gibson D, Fujikawa K.
Phospholipid binding properties of human placental anticoagulant protein-1, a member of the lipocortin family.
J Biol Chem.
1989;264:7944-7949 27. Crompton MR, Moss SE, Crumpton MJ. Diversity in the lipocortin/calpactin family. Cell. 1988;55:1-3[CrossRef][Medline] [Order article via Infotrieve]. 28. Swairjo MA, Concha NO, Kaetzel MA, Dedman JR, Seaton BA. Ca2+-bridging mechanism and phospholipid head group recognition in the membrane-binding protein annexin V. Nat Struct Biol. 1995;2:968-974[CrossRef][Medline] [Order article via Infotrieve]. 29. Tait JF, Sakata MS, McMullen BA, et al. Placental anticoagulant proteins: isolation and comparative characterization of four members of the lipocortin family. Biochemistry. 1988;27:6268-6276[CrossRef][Medline] [Order article via Infotrieve].
30.
Gilbert GE, Arena AA.
Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine.
J Biol Chem.
1996;271:11120-11125 31. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965;13:238-252[Medline] [Order article via Infotrieve]. 32. Johnson SM, Bangham AD, Hill MW, Korn ED. Single bilayer liposomes. Biochim Biophys Acta. 1971;233:820-826[Medline] [Order article via Infotrieve]. 33. Hope MJ, Bally MB, Webb G, Cullis PR. Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta. 1985;812:55-65[CrossRef]. 34. Chen P, Toribara T, Warner H. Microdetermination of phosphorus. Anal Chem. 1956;28:1756-1758[CrossRef].
35.
Neuenschwander PF, Morrissey JH.
Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII but not cofactor function: analysis of a mutant with a selective deficiency in activity.
J Biol Chem.
1992;267:14477-14482 36. Lollar P, Fass DN. Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone. Arch Biochem Biophys. 1984;233:438-446[CrossRef][Medline] [Order article via Infotrieve].
37.
Gilbert GE, Sims PJ, Wiedmer T, et al.
Platelet-derived microparticles express high affinity receptors for factor VIII.
J Biol Chem.
1991;266:17261-17268 38. Govers-Riemslag JW, Janssen MP, Zwaal RF, Rosing J. Prothrombin activation on dioleoylphosphatidylcholine membranes. Eur J Biochem. 1994;220:131-138[Medline] [Order article via Infotrieve].
39.
Andree HA, Stuart MC, Hermens WT, et al.
Clustering of lipid-bound annexin V may explain its anticoagulant effect.
J Biol Chem.
1992;267:17907-17912
40.
Huang C, Mason J.
Geometric packing constraints in egg phosphatidylcholine vesicles.
Proc Natl Acad Sci U S A.
1978;75:308-310
41.
Andree H, Reutelingsperger C, Hauptmann R, et al.
Binding of vascular anticoagulant 42. Ueno M, Tanford C, Reynolds JA. Phospholipid vesicle formation using nonionic detergents with low monomer solubility: kinetic factors determine vesicle size and permeability. Biochemistry. 1984;23:3070-3076[CrossRef][Medline] [Order article via Infotrieve].
43.
Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S.
Surface-dependent reactions of the vitamin K-dependent enzyme complexes.
Blood.
1990;76:1-16 44. Freyssinet JM, Gauchy J, Cazenave JP. The effect of phospholipids on the activation of protein C by the human thrombin-thrombomodulin complex. Biochem J. 1986;238:151-157[Medline] [Order article via Infotrieve].
45.
Suzuki K, Stenflo J, Dahlback B, Teodorsson B.
Inactivation of human coagulation factor V by activated protein C.
J Biol Chem.
1983;258:1914-1920 46. Connor J, Schroit A. Transbilayer movement of phosphatidylserine in erythrocytes: inhibition of transport and preferential labeling of a 31000-dalton protein by sulfhydryl reactive reagents. Biochemistry. 1988;27:848-851[CrossRef][Medline] [Order article via Infotrieve].
47.
Connor J, Bucana C, Fidler IJ, Schroit AJ.
Differentiation-dependent expression of phosphatidylserine in mammalian plasma membranes: quantitative assessment of outer-leaflet lipid by prothrombinase complex formation.
Proc Natl Acad Sci U S A.
1989;86:3184-3188 48. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207-2216[Abstract]. 49. Bevers E, Comfurius P, Zwaal R. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 1983;736:57-66[Medline] [Order article via Infotrieve]. 50. van Heerde WL, Poort S, van 't Veer C, Reutelingsperger CP, de Groot PG. Binding of recombinant annexin V to endothelial cells: effect of annexin V binding on endothelial-cell-mediated thrombin formation. Biochem J. 1994;302:305-312. 51. London F, Ahmad SS, Walsh PN. Annexin V inhibition of factor IXa-catalyzed factor X activation on human platelets and on negatively-charged phospholipid vesicles. Biochemistry. 1996;35:16886-16897[CrossRef][Medline] [Order article via Infotrieve]. 52. Nimpf J, Bevers EM, Bomans PH, et al. Prothrombinase activity of human platelets is inhibited by beta 2-glycoprotein-I. Biochim Biophys Acta. 1986;884:142-149[Medline] [Order article via Infotrieve]. 53. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost. 1996;75:49-55[Medline] [Order article via Infotrieve].
54.
McNeil HP, Simpson RJ, Chesterman CN, Krilis SA.
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).
Proc Natl Acad Sci U S A.
1990;87:4120-4124 55. Takeya H, Mori T, Gabazza EC, et al. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest. 1997;99:2260-2268[Medline] [Order article via Infotrieve]. 56. Bancsi LF, van der Linden IK, Bertina RM. Beta 2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost. 1992;67:649-653[Medline] [Order article via Infotrieve].
57.
Ceriani RL, Sasaki M, Sussman H, Wara WM, Blank EW.
Circulating human mammary epithelial antigens in breast cancer.
Proc Natl Acad Sci U S A.
1982;79:5420-5424
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. N. Waehrens, C. W. Heegaard, G. E. Gilbert, and J. T. Rasmussen Bovine Lactadherin as a Calcium-independent Imaging Agent of Phosphatidylserine Expressed on the Surface of Apoptotic HeLa Cells J. Histochem. Cytochem., October 1, 2009; 57(10): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Raymond and B. D. Shur A novel role for SED1 (MFG-E8) in maintaining the integrity of the epididymal epithelium J. Cell Sci., March 15, 2009; 122(6): 849 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Dasgupta, H. Abdel-Monem, P. Niravath, A. Le, R. V. Bellera, K. Langlois, S. Nagata, R. E. Rumbaut, and P. Thiagarajan Lactadherin and clearance of platelet-derived microvesicles Blood, February 5, 2009; 113(6): 1332 - 1339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Shao, V. A. Novakovic, J. F. Head, B. A. Seaton, and G. E. Gilbert Crystal Structure of Lactadherin C2 Domain at 1.7A Resolution with Mutational and Computational Analyses of Its Membrane-binding Motif J. Biol. Chem., March 14, 2008; 283(11): 7230 - 7241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Podlaha, D. M. Webb, and J. Zhang Accelerated Evolution and Loss of a Domain of the Sperm-Egg-Binding Protein SED1 in Ancestral Primates Mol. Biol. Evol., October 1, 2006; 23(10): 1828 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Gilbert Portable tissue factor to the rescue Blood, February 1, 2006; 107(3): 856 - 857. [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Kvistgaard, L. T. Pallesen, C. F. Arias, S. Lopez, T. E. Petersen, C. W. Heegaard, and J. T. Rasmussen Inhibitory Effects of Human and Bovine Milk Constituents on Rotavirus Infections J Dairy Sci, December 1, 2004; 87(12): 4088 - 4096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asano, M. Miwa, K. Miwa, R. Hanayama, H. Nagase, S. Nagata, and M. Tanaka Masking of Phosphatidylserine Inhibits Apoptotic Cell Engulfment and Induces Autoantibody Production in Mice J. Exp. Med., August 16, 2004; 200(4): 459 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Dietzen, K. L. Page, and T. A. Tetzloff Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity Blood, April 15, 2004; 103(8): 3038 - 3044. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
v
) or annexin V (
), in
the presence of 1.5 mM Ca++. Lipospheres were added, and
bound factor VIII was evaluated by flow cytometry after 10 minutes.
Liposphere membrane composition of PS-PE-PC was 4:20:76. The
inhibition curve was modeled under the assumption that the
Kd of factor VIII with lipospheres was 4.8 nM;
the Ki (×) for lactadherin, 0.5 nM.
), extruded vesicles (
), and LMVs (
and 
) contained 4% PS (top row) or
15% PS (bottom row). Effective concentrations of the vesicles for
supporting the prothrombinase complex were identified in phospholipid
titration experiments (A,D). Subsaturating phospholipid concentrations
were selected for inhibition experiments (open symbols; A,D). The
indicated phospholipid composition/concentration was added to factor
Xa, factor Va, prothrombin, and either lactadherin or annexin V. After
5 minutes, the reaction was quenched with EDTA, and thrombin was
measured with chromogenic substrate S-2238 in a kinetic microplate
reader. Lactadherin was an effective inhibitor of the prothrombinase
complex regardless of membrane curvature or PS content (B,E). In panel
B, × indicates Ki = 1 nM. In
contrast, inhibition by annexin V was inversely related to curvature
and directly related to PS content (C,F). The Ca++
concentration was 1.5 mM for sonicated vesicles of 4% PS (
) are representative of 3 experiments. Data from experiments with a tissue factor concentration
of 0.2 nM (
; C). Inhibition by
lactadherin at various concentrations was measured by means of 2-step
amidolytic assays for the production of factor Xa (A,C) or thrombin (B)
as described in "Materials and methods." The inhibitory
concentration of lactadherin was directly related to phospholipid
concentration. In the absence of phospholipid (C), lactadherin was an
inefficient inhibitor of the factor Xase complex. Data obtained at
various phospholipid concentrations were normalized for comparison of
relative inhibition by lactadherin. Phospholipid composition was at a
PS-PE-PC ratio of 4:20:76. Data displayed are from a single set of
experiments (A-B) or a single experiment representative of 3 experiments (C).
